GROWTH HORMONE AXIS / FAQ
Questions From the Study Record
Direct, citation-anchored answers, with evidence gaps stated as plainly as findings.
What is CJC-1295?
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), built on the first 29 amino acids of the natural human hormone with four substitutions added for protease resistance. In its 'DAC' (Drug Affinity Complex) form, a chemical linker binds the peptide to albumin, a blood protein, extending its activity from minutes to multiple days [8]. A short-acting version without that linker — often called Modified GRF (1-29) or no-DAC — is frequently confused with the DAC form in marketing and forum discussion, even though the two behave very differently. CJC-1295 is not approved for human use anywhere and is sold only as a research chemical.
What does CJC-1295 do?
CJC-1295 binds the GHRH receptor on pituitary cells, triggering the release of growth hormone (GH), which in turn raises IGF-1 in the liver. In the human studies actually published, a single dose raised mean plasma GH two- to ten-fold for six days or more, and IGF-1 one-and-a-half- to three-fold for nine to eleven days; after repeated doses, IGF-1 stayed above baseline for up to 28 days [4]. A related study found that GH's normal pulsatile release pattern was preserved even under this sustained stimulation [5]. That published effect is real and measured; it is not, however, evidence for any specific health benefit — no trial has tested CJC-1295 against a therapeutic outcome.
Is CJC-1295 safe?
There is no large or long-term safety trial to answer that question directly. What exists is a small set of early-phase pharmacology studies in healthy adults [4][5], plus mechanism-based cautions: growth hormone and IGF-1 elevation carries a theoretical, population-level association with certain cancers; sustained GH stimulation can cause fluid retention and reduced insulin sensitivity; and a 2024 FDA compounding-committee review cited immunogenicity concerns for GH secretagogues including CJC-1295. The compound's original long-acting development program was also discontinued, with a patient death from that era frequently cited alongside it, though a causal link to CJC-1295 was never established in the public record. None of this amounts to 'safe' or 'unsafe' — it amounts to thin evidence and several open mechanistic concerns.
How much CJC-1295 should I take?
This site does not recommend a dose for anyone. The published human pharmacology studies used single subcutaneous doses of 30, 60, or 90 micrograms per kilogram [4][5] — figures reported here only as a description of what those specific trials tested, not as guidance. No controlled trial has established a safe or effective human dosing regimen for any purpose, and 'protocols' circulating in research-use communities are not derived from such a trial.
What is CJC-1295 / Ipamorelin good for?
The intended logic is that CJC-1295 (acting on the GHRH receptor) and ipamorelin (acting on the separate ghrelin receptor, GHS-R1a) potentiate one another, producing a larger GH pulse together than either alone — a pattern suggested by cell studies showing roughly double the cAMP signal when both receptor pathways are activated together [9]. That mechanism-level plausibility is not the same as a demonstrated benefit: no controlled human trial has tested the fixed CJC-1295/ipamorelin combination against any outcome.
What are the bad side effects of CJC-1295 and Ipamorelin?
No blend-specific trial has measured this directly. A review of GH secretagogues as a class found them generally well tolerated, with increased blood glucose and reduced insulin sensitivity as the main metabolic concern, and noted that long-term cancer and mortality data are still needed [7]. Consistent with GH excess mechanistically, fluid retention, carpal-tunnel-like hand symptoms, and joint discomfort are also flagged as class-level concerns [7], layered on top of CJC-1295's own documented GH/IGF-1 elevation [4]. Research-use communities separately and consistently report injection-site reactions, transient water retention, and post-injection flushing, though these are anecdotal, not clinical evidence.
How long do CJC-1295 and Ipamorelin take to work?
The two halves work on very different timescales, and there is no published data for how they interact when dosed together. CJC-1295 alone, in its DAC form, raises GH for six or more days and IGF-1 for nine to eleven days after a single dose, with effects on IGF-1 persisting up to 28 days after repeated dosing [4]. Ipamorelin, by contrast, is understood to produce a single, much shorter GH pulse that clears within hours, though a formally published human pharmacokinetic study of ipamorelin alone does not appear to exist. No study has measured the combined timeline.
How many mg of CJC-1295 and Ipamorelin should I take?
This site does not recommend a dose. There is no published controlled trial of the two peptides dosed together, so there is no study-derived combined-dose figure to report at all — unlike the single-agent CJC-1295 studies, where specific doses were published [4][5] purely as a description of what was tested. Dosing schedules circulating in research communities for the combination are not derived from any controlled trial.
What does the MOTS-c peptide do?
MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA. Its best-characterized action is inhibiting the folate cycle inside cells, which activates AMPK, a master regulator of cellular energy use, primarily in skeletal muscle [15]. A 2024 study identified casein kinase 2 as a direct molecular binding target, with tissue-specific effects — activating in muscle, suppressing in fat — linked to muscle glucose uptake and prevention of muscle atrophy in mice [10]. Under metabolic stress, MOTS-c also moves from the mitochondrion into the cell nucleus to help regulate stress-response genes, including through the NRF2 pathway [14]. Every one of these findings comes from mouse or cell-culture experiments; none has been demonstrated in a human interventional study.
What are the negative side effects of MOTS-c?
There is no published human side-effect data for MOTS-c at all, because no controlled human trial has given anyone the peptide. The one study involving living human subjects measured an existing biomarker association in 94 chronic hemodialysis patients — a specific, severely ill population — not the effect of administering MOTS-c [11]. Any claim about side effects in humans would be speculation extrapolated from mouse and rat dosing studies, and this site declines to make that extrapolation.
Is MOTS-c legal to buy?
MOTS-c is not approved by the FDA for any human use, and it is sold by research suppliers as a laboratory research chemical, not as a product intended for human consumption. Anti-doping authorities treat it as a prohibited substance in elite sport, so tested athletes risk sanctions for use. This site does not sell, source, or recommend MOTS-c from any supplier, and does not offer an opinion on the legality of any specific purchase.
How often do you inject MOTS-c?
There is no published human injection-frequency protocol for MOTS-c, because no controlled human trial of the peptide as an intervention exists. The animal studies behind this page's findings used daily dosing over periods of days to weeks in mice and rats [13][15] — figures reported here only to describe what those specific experiments tested, not as a human recommendation. This site does not suggest an injection frequency for anyone.